IJBPAS, August, 2025, 14(8): 4437-4448

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

REMANUFACTURING AND SERVICING MEDICAL DEVICES-FDA

SUSHMA G[1], ABHISHEK BV[2*] AND GOUDANAVAR PS[3]

1: M Pharm, Department of Pharmaceutics & Regulatory Affairs, Sri Adichunchanagiri College of Pharmacy, B G Nagara, Karnataka, India

2: Assistant Professor, Department of Pharmaceutics & Regulatory Affairs, Sri Adichunchanagiri College of Pharmacy, B G Nagara, Karnataka, India

3: Professor, & Head Department of Pharmaceutics & Regulatory Affairs, Sri Adichunchanagiri College of Pharmacy, B G Nagara, Karnataka, India

***Corresponding Author: Dr. Abhishek B V: E Mail: abhishek17@accp.co.in**

Received 20th March 2024; Revised 24th April 2024; Accepted 22th Aug. 2024; Available online 1st Aug. 2025

https://doi.org/10.31032/IJBPAS/2025/14.8.9316

ABSTRACT

The study explores the realm of medical devices, which exceeds a global count of 1.5 million, characterized by stringent safety standards. It delves into remanufacturing, scrutinizing US regulations and proposing a definition to ease access to functional equipment in developing nations. The differentiation between remanufacturing and servicing is pivotal, particularly in terms of cybersecurity and device safety.

Investigating the regulatory landscape of medical equipment remanufacturing, this study is to examines the perspective of the United States Food and Drug Administration (USFDA). Given the limited regulatory framework in many developing countries, the role of the USFDA becomes pivotal in shaping the industry. The primary objective is to establish a clear and comprehensive definition for medical device remanufacturing within the US context. This, in turn, would promote standardized practices and instil confidence among consumers regarding remanufactured medical products. The envisioned definition holds significant potential for enhancing access to functional medical equipment through the practice of remanufacturing, particularly in resource-constrained regions.

The process of determining remanufacturing activities involves a thorough evaluation of intended use changes, their impact on specifications, the necessity for new marketing submissions, and meticulous assessment of component specifications. In this endeavour, the utilization of risk management principles, encompassing estimation and hazard evaluation, proves indispensable. The essence of robust

decision-making lies in documenting choices extensively, substantiated by validation data. This documentation serves to clarify how activities influence performance, safety specifications, and intended use.

Keywords: USFDA, OEM, ISO, Medical Devices, Cybersecurity, Re- Manufacturing

INTRODUCTION:

Medical devices encompass a wide spectrum, including devices, programs, medications, or related products created to diagnose, prevent, treat, or alleviate disorders. This diverse category exceeds 1.5 million globally, spanning from advanced instruments to commonplace items like pacemakers, divided into over ten thousand distinct categories.

Medical equipment stands apart from products in other sectors due to their stringent safety requirements, directly impacting human health. Unlike other products, they can affect patients directly and failure can lead to serious consequences. Medical device regulations are designed to ensure patient safety and access to quality equipment. While remanufacturing medical equipment is studied from different angles, there's a lack of insight into how it's practiced and its regulatory aspects. This study aims to analyze US regulations related to medical equipment remanufacturing and propose a definition for remanufacturing that supports access to functional equipment in developing countries, addressing current unsustainable practices.

To materially alter a finished product in a way that jeopardizes its intended performance, safety, or use is to remanufacture a medical device. This is not the case with servicing, which is handled differently by the FDA. In particular, when those devices are used on several patients over a prolonged length of time, the effectiveness of the devices and the US healthcare system both depend on the accessibility of high-quality maintenance and repair. Inadequate servicing can cause equipment to malfunction, have unfavourable effects, and degrade

performance. Additionally, a critical challenge for individuals who maintain medical devices is cybersecurity **[1]**.

DISCUSSION:



Figure 1: Flowchart showing FDA's end-of-life actions for medical equipment. Currently, there are no rules for operators in this category from the FDA [2]



Figure 2: Principles: FDA suggests utilizing the following guiding principles to assist assess if activities are remanufacturing when applying this guidance [3]



Figure 3: Flowchart for identifying whether certain actions taken qualify as remanufacturing

The flow chart discusses guidelines from the FDA regarding the assessment of activities related to medical device reprocessing and biocompatibility. These guidelines are aimed at ensuring that any changes made to medical devices do not compromise their safety or performance when they come into contact with human body tissues, including both patients and healthcare providers. Here some key points:

1A.- Replace add, or remove a component or portion contact that is directly or indirect

1. **Direct and Indirect Contact:** When they come into physical contact with body tissues, devices or parts, such catheter tubing used on a patient, can have direct contact with the tissues. When liquids or gases pass through a component, such as the components in a catheter hub, before getting into touch with bodily tissue, this is known as indirect contact.
2. **Assessment of Activities:** It is important for organizations to consider how their actions can alter approved reprocessing instructions or result in unacceptably bad biological reactions. This evaluation takes into account both direct and indirect contact with patients or device users.
3. **Changes to Components:** If any addition, removal, or change to a component or material on the finished device directly or indirectly contacts body tissue, the answer to the assessment question (1A) should be "yes." This also applies when previously unexposed components/materials are introduced to such contact.
4. **Material Changes:** A "yes" response to 1A should also be given for any alteration to a component or substance that directly or indirectly comes into contact with physiological tissue.
5. **Uncertainty:** If the entity is uncertain about how to respond to A1, the answer should still be "yes" to ensure thorough evaluation.
6. **Not Remanufacturing**: Any activity that receives a "yes" in response to 1A is not always considered to be remanufacturing. Instead, it signifies the requirement to assess how the change may affect the equipment's performance and safety standards, as mentioned in 1A.1.
7. **No Contact:** If no component/part/material added, removed, or changed directly or indirectly contacts body tissue, the answer to 1A should be "no," and the assessment can proceed to 1B

1A.1-Have the device's performance or

safety requirements changed significantly?

It appears that you have provided a passage that discusses regulatory considerations related to medical devices, specifically focusing on activities that involve components, materials, or processes that come into contact with body tissues and their potential impact on biocompatibility and reprocessing instructions. This passage outlines the need for a risk-based assessment to determine whether a significant change has occurred that might classify the activity as "remanufacturing."

Here is a breakdown of the key points in the passage:

1. **Types of Activities:** The passage mentions that certain activities involving components, parts, or materials that come into contact with body tissue (either directly or indirectly) should be assessed. This includes activities that expose previously unexposed components or materials to body tissue.
2. **Purpose of Assessment:** The primary purpose of the assessment is to determine whether there is a significant change in the biocompatibility or the validated reprocessing instructions of a legally marketed medical device.
3. **Remanufacturing Consideration:** If the activity results in a significant change, it may be considered "remanufacturing" of the device. The classification of remanufacturing depends on the magnitude of the change and the nature of the component/part/material being altered.
4. **Reprocessing Validation and Biocompatibility Testing:** Depending on the nature and extent of the change, reprocessing validation and comprehensive biocompatibility risk assessment or testing may be required.
5. **Factors to Consider:** Entities should take into account various factors that can affect reprocessing and biocompatibility, including materials of construction, material processing methods, sterilization processes, any residuals from aids used in the process, and the intended use life of the legally marketed device.
6. **Impact on Reprocessing Instructions:** Remanufacturing is probably defined as operations that affect the suitability of the verified reprocessing procedures for the legally sold device.
7. **Decision Tree:** The passage suggests a decision tree where the answer to question 1A.1 determines

whether the activity is likely remanufacturing. If the answer is "yes," it's likely remanufacturing; if the answer is "no," further questions (1B, etc.) may need to be considered.

1B-Modify the dimensional or performance requirements of a component part or material or add or delete one?

Answer "yes" to question 1B if the action entails adding or removing a component, part, or material that wasn't initially included in the device or if a component, part, or material is deleted without a replacement. This holds true whether an original equipment manufacturer (OEM) component, part, or material is used in place of an identical OEM product or a non-OEM product.

Changing the dimensions or performance criteria: If any changes or replacements are made to a part, component, or material, the response should be "yes" if such changes affect how well they operate. If such modifications have not been made, the suitable

This passage provides a detailed set of considerations for determining whether an activity involving a medical device qualifies as "remanufacturing" based on changes to components, dimensional specifications, or performance specifications. Here's a summary:

1. **Effect on Device Performance or Safety:** To assess whether the addition or removal of a component significantly changes the device's performance or safety specifications, entities should consider the device's intended use life. Reusable devices, for example, undergo multiple reprocessing cycles within their intended use life. The assessment should determine if the added or removed component can withstand these cycles. This may involve verification, validation testing, or a risk-based assessment. If the device cannot withstand the cycles, it's likely a significant change.
2. **Changed Dimensional Specifications:** When evaluating changes in dimensional specifications, entities should not only consider the magnitude of the change but also the criticality of the modified dimension. If dimensional specifications fall within an acceptable range, the answer to 1B.1 is likely "no." However, if changes go beyond this acceptable range, the answer is likely "yes."
3. **Changed Performance Specifications:** Similar to this, entities should think about whether changes to performance standards still fit inside acceptable tolerance

limits. If the performance falls within these parameters, the answer to 1B.1 is probably "no." The answer is probably "yes" if adjustments cause performance to deviate from the acceptable range.

4. **Remanufacturing Determination:** If the answer to 1B.1 is "yes" for any of the three categories (effect on device performance or safety, dimensional specifications, or performance specifications), the activity is likely classified as remanufacturing. If the answer to 1B.1 is "no" for all categories, the assessment proceeds to 1C for further evaluation.

1B.1 Have the device's performance or safety requirements changed

Several factors must be taken into account when determining whether the performance or safety requirements of a medical device are significantly altered by the addition or removal of a component, part, or material.

Intended Use Life: Take into account if the component that was added or removed is designed to withstand numerous reprocessing cycles within the device's intended use life. If not, it might have a severe impact on the device's functionality and security.

Dimensional Specifications: Determine whether modifications to the component's dimensional specifications have a substantial effect on the functionality or security of the device. This comprises both the criticality of the affected dimension and the size of the change. Changes that fall within an allowed range might not have a big impact on the device, but those that go outside it might.

Performance standards: Determine whether modifications to the component's performance standards have a substantial impact on the functionality or safety of the device.

1C. Is there a new or modified risk or is there a change in the performance or safety specifications?

It's crucial to undertake a thorough evaluation of any activity done on a medical device that has been legally marketed in order to ascertain whether there are any new or elevated dangers or if the device's safety requirements have changed. These are the main factors to think about:

Utilize a risk-based strategy to determine whether the action, as contrasted to the lawfully marketed equipment, adds new hazards or enhances the chance of existing dangers. Both the cumulative changes made to the device and the individual alterations should be taken into account in this evaluation.

Recognize that cumulative effects of several changes may result in a major influence on the device's performance or safety

requirements, even though individual changes don't necessarily have that effect.

1C.1 Have the device's performance or safety requirements changed

Compliance depends on knowing whether a change to a medical device materially alters its performance or safety requirements. The alteration most certainly qualifies as "remanufacturing" and is subject to rigorous regulatory review if it adds new risks, changes safety features, or has cumulative effects that are significant. Contrarily, if the modification has no appreciable influence on the or safety, it may be regarded as "servicing," but adherence to applicable laws is still necessary to maintain the device's efficacy and security.

Changes involving software [3, 4]

- Because they usually require remanufacturing due to the way they change product architecture, requirements, and anomalies, software upgrades shouldn't be covered by Section VI. Since software upgrades don't significantly change the performance or safety requirements of the device, they shouldn't be subject to the FDA's risk-based review approach. Restoring device specs and intended use, authorized by the OEM.
- Running hardware diagnostics.
- Checking for cybersecurity issues.
- Reinstalling OEM software.
- Enabling/disabling connectivity features.
- Data backup and recover.
- Managing user accounts.
- Accessing diagnostic information.

Other operations involving software alterations are more likely to materially alter the performance or safety requirements of a device, making remanufacturing more likely. The entity must, however, properly document its decision-making if it thinks that an action requiring a change to software won't materially alter a device's

performance or safety requirements.

Remanufacturing is any software-related activity that dramatically alters a device's intended usage. The unintended results and cumulative repercussions of any software change(s) should also be taken into account by entities. When executing operations on devices, organizations should decide if each operation, as well as the overall impact of the changes produced, constitutes remanufacturing and should explain why.

Considerations for labeling

Based on information that is readily available to the public and the FDA's efforts stated in Section II.A of this draft advise; FDA should ensure that OEMs of reusable devices plan for their equipment to routinely undergo both preventative repairs and preventative maintenance. Devices of this type should come with guidelines on how to properly restore them to the performance and safety requirements established by the OEM. Accidental remanufacturing may occur when businesses lack the instructions necessary to return a product to its original performance and safety standards. Inadequate servicing instructions may make it harder to find gadgets that are high-quality, safe, and effective.

FDA urges OEMs to publish servicing instructions that simplify routine maintenance and repair of their reusable devices as an industry standard practice in order to promote and protect the public health. To promote routine device maintenance and repair, the FDA advises that the labeling of reusable devices include the following information, where appropriate:

1. **Key Performance and Safety Specifications**:
   Include important technical and functional parameters such as the device's size, electrical make-up, internal fuses, voltage, amperage, and frequency, as well as flow rate accuracy, humidity, temperature, and other performance requirements.
2. **Recommended Maintenance:**
   Detailed information on recommended maintenance activities and schedule.
3. **Routine Testing and Acceptance Criteria:** Specified acceptance criteria and suggestions for routine testing to ensure that the device meets its performance and safety requirements
4. **Device Feedback and Alerts:**
   Description of error codes, alerts, and alarm features present on the device to aid in troubleshooting.
5. **Precautions and Warnings:**
   Clear instructions regarding precautions and warnings relevant to servicing the device, ensuring safety during maintenance.
6. **Software Information:**

Version number and release data

CONCLUSION:

This study explores the complex remanufacturing of medical devices, focusing on its potential to provide functional medical equipment to developing nations. It examines the US Food and Drug Administration's role in shaping industry practices, aiming to standardize practices and increase accessibility. The remanufacturing process requires rigorous assessment of intended use changes, specifications, regulatory submissions, and component specifications.

Robust risk management principles are essential, and effective decision-making relies on comprehensive documentation and validation data. The outcome of the study is to standardized practices and enhanced access to functional medical equipment, addressing healthcare to ensure safe & effective for Intended use.

REFERENCES:

[1] Center for Devices and Radiological Health. Remanufacturing and Servicing Medical Devices [Internet]. FDA; [cited 2023 Sept 1]. Available from: https://www.fda.gov/medical-devices/quality-and-compliance-medical-devices/remanufacturing-and-servicing-medical-devices#introduction

[2] Eze S, Ijomah W, Wong TC. Accessing medical equipment in developing countries through remanufacturing - journal of remanufacturing [Internet]. Springer Netherlands; 2019 [cited 2023 Sept 1]. Available from: https://link.springer.com/article/10.1007/s13243-018-0065-7

[3] [Internet]. [cited 2023 Sept 1]. Available from: https://www.fda.gov/media/150141/download

[4] [Internet]. [cited 2023 Sept 6]. Available from: https://www.fda.gov/media/117238/download